Trinity Biotech Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
John Gillard
Chief executive officer
US$710.0k
Total compensation
| CEO salary percentage | 66.6% |
| CEO tenure | 4.2yrs |
| CEO ownership | n/a |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding
Sep 25
A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb
Aug 07The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More
Jun 11Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%
Mar 02Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry
Dec 18A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)
Sep 12Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?
Aug 08Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price
Jun 09Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)
Apr 23This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts
Apr 23Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 01Trinity Biotech appoints former GE executive Aris Kekedjian as CEO
Oct 03At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?
Sep 01Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
Jun 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$20m |
| Jun 30 2024 | n/a | n/a | -US$22m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$710k | US$473k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$34m |
| Dec 31 2022 | US$863k | US$452k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$593k | US$346k | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$2m |
| Mar 31 2021 | n/a | n/a | -US$2m |
| Dec 31 2020 | US$312k | US$52k | -US$6m |
Compensation vs Market: John's total compensation ($USD710.00K) is about average for companies of similar size in the US market ($USD645.37K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Gillard (43 yo)
4.2yrs
Tenure
US$710,000
Compensation
Mr. John Gillard is President & CEO of Trinity Biotech plc since December 17, 2023 and served as Chief Financial Officer since November 17, 2020 until December 17, 2023. He serves as Executive Director at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.2yrs | US$710.00k | no data | |
| Founder | no data | US$80.00k | 5.14% $ 739.4k | |
| Executive Director of Business Development & Executive Director | no data | US$50.00k | 0.74% $ 106.0k | |
| CFO & Chief Accounting Officer | less than a year | no data | no data | |
| Director of Operations | no data | no data | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Information Officer | 9.3yrs | no data | no data | |
| Group Director of Human Resources & Culture | no data | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
51yo
Average Age
Experienced Management: TRIB's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.2yrs | US$710.00k | no data | |
| Founder | 2.3yrs | US$80.00k | 5.14% $ 739.4k | |
| Executive Director of Business Development & Executive Director | 18yrs | US$50.00k | 0.74% $ 106.0k | |
| Independent Director | 1.3yrs | US$10.00k | 0% $ 0 | |
| Independent Non-Executive Director | 2.3yrs | US$63.00k | 0% $ 0 |
2.3yrs
Average Tenure
67yo
Average Age
Experienced Board: TRIB's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 12:19 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Trinity Biotech plc is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura McGuigan | B. Riley Securities, Inc. |
| Lawrence Solow | CJS Securities, Inc. |
| William Bonello | Craig-Hallum Capital Group LLC |